Skip to content

Retrospective analysis of long-term prognostic factors for non-small cell lung cancer with EGFR gene mutation in Nagano Prefecture

Retrospective analysis of long-term prognostic factors for non-small cell lung cancer with EGFR gene mutation in Nagano Prefecture - Retrospective analysis of long-term prognostic factors for non-small cell lung cancer with EGFR gene mutation in Nagano Prefecture (Re ALPS)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000057193
Enrollment
300
Registered
2025-03-05
Start date
2025-01-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer with EGFR gene mutation

Interventions

None listed

Sponsors

Shinshu University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Cases of non-small cell lung cancer that have been proven histologically or cytologically and are subject to medical treatment. (2) Mutations are recognized in approved companion diagnostics using tumor tissue or cells. (3) Age is 20 years or older.

Exclusion criteria

Exclusion criteria: Those deemed inappropriate for participation in this research by the principal investigator or research collaborators.

Design outcomes

Primary

MeasureTime frame
NLR (Neutrophil-to-Lymphocyte Ratio)

Secondary

MeasureTime frame
Site of occurrence, maximum tumor diameter, site of metastasis, type of genetic mutation, treatment details after secondary treatment and whether ICI or EGFR-TKI was used, PLR(Platelet-to-Lymphocyte Ratio), GPS(Glasgow Prognostic Score), PNI(Prognostic Nutritional Index), etc.

Countries

Japan

Contacts

Public ContactKatsuya Yanagisawa

Shinshu University School of Medicine First Department of Internal Medicine

6367katsu@shinshu-u.ac.jp0263-37-2631

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026